Association of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors with Cardiovascular Events and Death in Dialysis Patients: A Systematic Review and Meta-Analysis
Blood Purification · 2023
DOI: 10.1159/000531274 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Blood Purification, 2023. Verfasst von Maria Gabriela Motta Guimarães und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cardiorenal Division, Hospital Ana Nery, Salvador, Brazil. Hauptthemen laut MEDLINE: Prolyl-Hydroxylase Inhibitors, Hematinics, Renal Insufficiency, Chronic, Thrombosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Background
Anemia is a common finding among patients with advanced chronic kidney disease, especially those on dialysis. The recent introduction of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) has raised some concerns about the cardiovascular and thrombotic complications of this class of drugs.
Objectives
This meta-analysis aimed to assess the safety of HIF-PHIs in patients with end-stage kidney disease (ESKD) versus standard therapy with erythropoiesis-stimulating agents (ESAs).
Methods
Databases were searched on April 2022. Studies that reported incidence of all-cause mortality; major cardiovascular adverse events (MACEs); myocardial infarction (MI); stroke and thrombotic events in the use of HIF-PHIs or ESA on ESKD patients in hemodialysis or peritoneal dialysis were evaluated. Data were extracted from published reports, and quality assessment was performed per Cochrane recommendations.
Results
12,821 patients from ten randomized controlled trials were included in this study. Most patients (83%) were on hemodialysis. 6,461 (50.3%) were using HIF-PHIs, and 6,360 (49.6%) were in the ESA group. The pooled estimated incidence of all-cause mortality was 769 in the HIF-PHIs group (relative-risk ratios (RR): 1.04; confidence interval (CI): 0.95–1.14; p = 0.52; I2 = 0%). There was no difference in the groups regarding the outcomes of MACE in the analysis of the three studies that reported this outcome (RR: 0.95; CI: 0.87–1.04; p = 0.69; I2 = 0%). In addition, there was no statistical difference among the outcomes of MI, stroke, or thrombotic events.
Conclusions
Among patients with ESKD on dialysis, the use of HIF-PHIs was non-inferior regarding the safety outcomes when compared to standard of care therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiorenal Division, Hospital Ana Nery, Salvador, Brazil.
- Medicine and Health Program, Federal University of Bahia, Salvador, Brazil.
- Bahiana School of Medicine and Public Health, Salvador, Brazil.
Zitieren
APA
Guimarães, M. G. M., Tapioca, F. P. M., Neves, F. C., Moura-Neto, J. A., & Passos, L. C. S. (2023). Association of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors with Cardiovascular Events and Death in Dialysis Patients: A Systematic Review and Meta-Analysis. Blood Purification. https://doi.org/10.1159/000531274
Vancouver
Guimarães MGM, Tapioca FPM, Neves FC, Moura-Neto JA, Passos LCS. Association of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors with Cardiovascular Events and Death in Dialysis Patients: A Systematic Review and Meta-Analysis. Blood Purification. 2023. doi:10.1159/000531274
BibTeX
@article{Guimares2023,
author = {Guimarães, Maria Gabriela Motta and Tapioca, Fernanda Pinheiro Martin and Neves, Felipe Costa and Moura-Neto, José A and Passos, Luiz Carlos Santana},
title = {Association of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors with Cardiovascular Events and Death in Dialysis Patients: A Systematic Review and Meta-Analysis},
journal = {Blood Purification},
year = {2023},
doi = {10.1159/000531274}
}
EUVIMED